885591-80-0

Basic information

• Product Name: 1H-Indazole-3-carboxamide, 1-(3-amino-1,2-benzisoxazol-5-yl)-6-[4-[2-[(dimethylamino)methyl]-3-pyridinyl]-2-fluorophenyl]-7-fluoro-
• Synonyms: 1-(3-amino-1,2-benzoxazol-5-yl)-6-[4-[2-[(dimethylamino)methyl]pyridin-3-yl]-2-fluorophenyl]-7-fluoroindazole-3-carboxamide;1H-Indazole-3-carboxaMide, 1-(3-aMino-1,2-benzisoxazol-5-yl)-6-[4-[2-[(diMethylaMino)Methyl]-3-pyridinyl]-2-fluorophenyl]-7-fluoro-
• CAS NO: 885591-80-0
• Molecular Formula: C29H23F2N7O2
• Molecular Weight: 539.544
• Mol File: 885591-80-0.mol

Chemical Properties

• CAS DataBase Reference: 1H-Indazole-3-carboxamide, 1-(3-amino-1,2-benzisoxazol-5-yl)-6-[4-[2-[(dimethylamino)methyl]-3-pyridinyl]-2-fluorophenyl]-7-fluoro-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indazole-3-carboxamide, 1-(3-amino-1,2-benzisoxazol-5-yl)-6-[4-[2-[(dimethylamino)methyl]-3-pyridinyl]-2-fluorophenyl]-7-fluoro-(885591-80-0)
• EPA Substance Registry System: 1H-Indazole-3-carboxamide, 1-(3-amino-1,2-benzisoxazol-5-yl)-6-[4-[2-[(dimethylamino)methyl]-3-pyridinyl]-2-fluorophenyl]-7-fluoro-(885591-80-0)

Safety Data

• Hazardous Substances Data: 885591-80-0(Hazardous Substances Data)

Usage

Type

Complex chemical compound

Primary use

Pharmaceutical research and development

Target protein

Tankyrase

Potential application

Cancer therapy

Biological activity

Potent inhibitor of tankyrase

Pre-clinical models

Exhibits strong anti-proliferative and anti-tumor activity

Fluorinated and aromatic substructures

Valuable tool for understanding structure-activity relationships of similar compounds and their biological mechanisms

Importance

Intricate molecular structure and specific biological activity make it an important and valuable chemical in the field of medicinal chemistry

Upstream product

• 1007346-66-8 C₂₉H₂₁F₃N₆O 
• 546-88-3 acetylhydroxamic acid 

Relevant articles and documents

7-Fluoroindazoles as potent and selective inhibitors of factor Xa

We have developed a novel series of potent and selective factor Xa inhibitors that employ a key 7-fluoroindazolyl moiety. The 7-fluoro group on the indazole scaffold replaces the carbonyl group of an amide that is found in previously reported factor Xa inhibitors. The structure of a factor Xa cocrystal containing 7-fluoroindazole 51a showed the 7-fluoro atom hydrogen-bonding with the N-H of Gly216 (2.9 ?) in the peptide backbone. Thus, the 7-fluoroindazolyl moiety not only occupied the same space as the carbonyl group of an amide found in prior factor Xa inhibitors but also maintained a hydrogen bond interaction with the protein's β-sheet domain. The structure-activity relationship for this series was consistent with this finding, as the factor Xa inhibitory potencies were about 60-fold greater (ΔΔG ≈ 2.4 kcal/mol) for the 7-fluoroindazoles 25a and 25c versus the corresponding indazoles 25b and 25d. Highly convergent synthesis of these factor Xa inhibitors is also described.

FACTOR XA COMPOUNDS

The present invention is directed to novel compounds of Formula (I) and forms and pharmaceutical compositions thereof, and the use thereof as inhibitors of Factor Xa.